Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (10,546)	$ (79,231)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Acquired in-process research and development	0	84,478
Share-based compensation expense	1,772	644
Depreciation and amortization	54	16
Change in fair value of preferred stock warrant liability	0	290
Change in operating assets and liabilities:
Prepaid expenses and other assets	(1,455)	(2,447)
Other assets	142	455
Accounts payable	321	(409)
Accrued expenses	(1,650)	(1,250)
Lease liabilities, net	(1)	5
Net cash (used in) provided by operating activities	(11,363)	2,551
Investing activities
Cash acquired in connection with the Merger	0	17,143
Net cash provided by investing activities	0	17,143
Financing activities
Issuance of common stock, net of issuance costs	1	62,317
Exercise of warrants and stock options to purchase common stock	7	81
Net cash provided by financing activities	8	62,398
Net increase (decrease) in cash and cash equivalents	(11,355)	82,092
Cash and cash equivalents at beginning of period	103,554	47,089
Cash and cash equivalents at end of period	92,199	129,181
Supplemental disclosure of cash flow information
Interest paid	102	84
Noncash financing activities
Warrant liability reclassification to equity	0	396
Issuance of convertible preferred stock upon merger	0	5,452
Conversion of convertible preferred stock into common stock upon Merger	0	83,302
Issuance of common stock upon Merger	$ 0	$ 97,982